A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See ...

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp ...

In this special bonus episode Talking General Practice speaks to consultant nephrologist Dr Shafi Malik about the heightened ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market ...

An announcement from Alnylam Pharma ( ($ALNY) ) is now available. On December 10, 2025, Alnylam Pharmaceuticals announced it had entered into ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

Lululemon Athletica, Inc. is among the companies set to leave the Nasdaq 100 Index as part of the benchmark’s annual ...

Alnylam Pharmaceuticals recently announced past and upcoming Board changes, with long-serving directors Mike Bonney and Carolyn Bertozzi, Ph.D., stepping down and industry veteran Stuart Arbuckle ...